Osteoarthritis in India

Prevalence and Impact

Osteoarthritis (OA) is the most common musculoskeletal disorder in India, affecting over 62 million individuals. The prevalence of OA in the population ranges between 22% and 30%. As the Indian population continues to age, the incidence of OA is expected to increase significantly.

Current Treatment Practices

The reliance on analgesics for OA management is notable, with a self-medication rate of 64.4%. Commonly used medications include paracetamol and ibuprofen, which reflect a treatment approach that emphasizes pain relief rather than addressing the disease’s underlying causes. Although these medications effectively alleviate OA symptoms, they fail to combat the progressive degeneration of cartilage. Furthermore, the long-term use of these painkillers raises concerns about cardiovascular and gastrointestinal risks, which are critical factors in managing chronic conditions. This situation highlights a therapeutic gap that necessitates additional strategies targeting both symptom relief and structural conservation.

Bridging the Therapeutic Gap in OA

Emerging Treatment Approaches

To improve OA management, disease-modifying strategies are essential. While maintaining joint health through exercise and dietary changes remains fundamental, recent evidence suggests that targeted immunomodulation could enhance standard care. Undenatured type II collagen (UC-II) represents a promising intervention, fostering oral immune tolerance through gut-associated lymphoid tissue. This process stimulates the generation of T-regulatory cells, which help modulate the autoimmune response against articular cartilage. Unlike long-term NSAID use, UC-II provides therapeutic advantages without the associated cardiovascular and gastrointestinal risks.

Shifting Therapeutic Goals

The focus of OA treatment is evolving from merely controlling symptoms to proactively preserving joint health. Given that cartilage degradation is progressive, it is vital that efforts to halt disease activity occur alongside pain management.

Clinical Evidence for UC-II in Osteoarthritis

Indian Real-World Multicentric Experience

A prospective, non-interventional study conducted across 18 centers in India assessed the efficacy of undenatured type II collagen (UC-II) at a dosage of 40 milligrams per day in 291 OA patients over a 90-day period. The study’s efficacy evaluation revealed significant improvements in the Western Ontario McMaster Osteoarthritis Index (WOMAC) scores. Scores improved from a baseline of 59.7 ± 19.6 to 39.0 ± (59.7 − 20.7) by day 90, indicating a mean change of −20.7 ± 12.6.